Efficacy of the medical compound of teneligliptin 20 mg and canagliflozin 100 mg with Free Style Libre

Efficacy of the medical compound of teneligliptin 20 mg and canagliflozin 100 mg with Free Style Libre - Efficacy of the medical compound of teneligliptin and canagliflozin with Free Style Libre

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029015

Enrollment

Registered

2017-09-05

Start date

2017-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

We continue same dose of any antidiabetic drugs except for teneligliptin and canagliflozin. Patients are equipped with a Free Style Libre for 14 days from the start of study. Teneligliptin 20 mg or

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Out-patients with type 2 diabetes whose HbA1c are more than 6.5% and less than 15% and who have no changes of diabetic treatment (e.g. diet therapy, exercise cure, medication) within the past 12 weeks and who have been treated with teneligliptin 20 mg or canagliflozin 100 mg.

Exclusion criteria

Exclusion criteria: 1. Patients who have renal dysfunction (eGFR is less than 30ml/min/1.73m2) 2. Pregnant women 3. Patients judged by the doctor to be ineligible

Design outcomes

Primary

Measure	Time frame
Blood glucose transition (standard deviation and MAGE), and average blood glucose level by a Free Style Libre.	—

Secondary

Measure	Time frame
Diabetes Treatment Satisfaction: DTSQ, glycoalbumin, urine albumin creatinine ratio, eGFR, glucagon, bodyweight.	—

Countries

Japan

Contacts

Public ContactTakahiro Tosaki

TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology Diabetes and Endocrinology

nrd49075@nifty.com052-800-2333

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026